Cortical Dynamics has worked with BPH Energy and Swinburne University of Technology (SUT) to develop and commercialise a unique depth of anaesthesia monitoring system for use during major surgery. The core technology is based on real time analysis of the patients electroencephalograph (EEG) using a proprietary algorithm based on a mathematically and physiologically detailed understanding of the brain’s rhythmic electrical activity.
Advent Energy Limited
BPH Energy currently holds a passive interest in unlisted Australian exploration company Advent Energy Limited.
Advent Energy holds a strong portfolio of exploration assets throughout Australia, with its cornerstone project lying off the coast of NSW in Petroleum Exploration Permit 11 (PEP 11).
Advent Energy, through its wholly owned subsidiary Asset Energy Pty Ltd, is planning to drill a well at the Baleen prospect PEP 11 in this highly prospective permit. The offshore Sydney Basin contains all the elements seen in other producing world class structures. The PEP11 permit covers 4,576 km2 on the doorstep of Australia’s largest energy market and extensive gas infrastructure.
Advent assumed operatorship of PEP11 in 2008 and has since generated an extensive accumulation of data demonstrating an active hydrocarbon system in what is considered a proven petroleum basin. The permit has recently been estimated to contain 13.2 trillion cubic feet (TCF) prospective recoverable gas resources (at the P50 or ‘best estimate’ level).
Advent has an 85% interest in the permit.
Molecular Discovery Systems (MDSystems)
This new class of anti-mitotic drugs, discovered by MDSystems cancer cell biology researcher Dr Robin Scaife, has undergone extensive development toward pre-clinical testing of anti-cancer activity. Detailed analyses of chemical analogues of the new drug have yielded a new drug that exhibits nearly 1000 times the biological activity of the initial compound derived by the aforementioned screening process. The new drug has undergone testing in animals to rule out adverse toxic side effects and is, therefore, primed for pre-clinical testing of anti-tumour activity.
MDSystems has been working with the Western Australian Institute for Medical Research (WAIMR) to develop and validate HLS5 as a novel tumour suppressor gene. A concerted research effort by leading Australian scientists has revealed that HLS5 works through multiple pathways that may target cancer as well as a range of other diseases such as Huntington’s, Parkinson’s and HIV infection.
MDSystems has developed patents and has exclusive rights to the tumour suppressor gene HLS5, both as a potential therapeutic target and also underpinning its involvement in a variety of disease pathways.